Well Referenced

Tag: appetite suppressant

Effects of 15-d Repeated Consumption of Hoodia gordonii Purified Extract on Safety, Ad Libitum Energy Intake, and Body Weight in Healthy, Overweight Women: A Randomized Controlled Trial

This 15-day randomized, double-blind, placebo-controlled trial evaluated the safety and efficacy of Hoodia gordonii purified extract (HgPE) in 49 healthy overweight women. Participants consumed 2 servings per day of 1110 mg HgPE or placebo in a yogurt drink. The HgPE group experienced adverse effects such as nausea, vomiting, and skin

Read More »
June 26, 2025 No Comments

Comparison of Continuous and Intermittent Anorectic Therapy in Obesity

This 1968 randomized controlled trial assessed the efficacy of continuous versus intermittent anorectic therapy in 108 obese patients over 28 weeks. Participants were divided into three groups: continuous phentermine, intermittent phentermine (alternating with placebo), and continuous placebo. Both phentermine groups achieved significantly greater weight loss compared to placebo. Notably, the

Read More »
June 26, 2025 No Comments

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

This 2010 double-blind, randomized controlled trial (BLOOM) evaluated the efficacy and safety of lorcaserin, a selective 5-HT₂C receptor agonist, in 3,182 overweight or obese adults over 52 weeks. Participants received lorcaserin 10 mg twice daily or placebo, alongside lifestyle counseling. At 1 year, 47.5% of the lorcaserin group lost ≥5%

Read More »
June 26, 2025 No Comments

Randomized trial of lifestyle modification and pharmacotherapy for obesity

This 2005 randomized, controlled trial assessed the efficacy of combining sibutramine (15 mg daily) with lifestyle modification in 224 obese adults over one year. Participants were assigned to one of four groups: sibutramine alone, lifestyle modification alone, sibutramine plus lifestyle modification, or sibutramine plus brief lifestyle counseling. All groups followed

Read More »
June 26, 2025 No Comments

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

This 12-month, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of pramlintide, an amylin analog, as an adjunct to lifestyle intervention (LSI) in 411 obese, non-diabetic adults. Participants were assigned to various dosing regimens of pramlintide (120, 240, or 360 µg administered twice or three times daily) or placebo,

Read More »
June 26, 2025 No Comments

Study of phendimetrazine bitartrate as an appetite suppressant in relation to dosage, weight loss and side effects

This 1962 study by Le Riche and Van Belle evaluated the efficacy and safety of phendimetrazine bitartrate as an appetite suppressant in obese patients. Participants received varying doses of phendimetrazine, and outcomes were assessed in terms of weight loss and side effects. The study found that phendimetrazine effectively suppressed appetite

Read More »
June 26, 2025 No Comments

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

This 56-week, randomized, placebo-controlled trial assessed the efficacy and safety of controlled-release phentermine/topiramate (PHEN/TPM CR) in 1,267 adults with class II or III obesity (BMI ≥35 kg/m²). Participants were randomized to receive placebo, PHEN/TPM CR 3.75/23 mg, or PHEN/TPM CR 15/92 mg, alongside a reduced-calorie diet. At week 56, mean

Read More »
June 26, 2025 No Comments